Drug intelligence / Profile preview

Mecoturn Q10

Development stage: Unknown
Lead developer: Admire Lifesciences
Modality: Small Molecules
Administration: Oral

Overview

Mecoturn Q10 is an oral multi-ingredient dietary supplement marketed by Admire Lifesciences for the management of diabetic neuropathy and nutritional deficiencies. It is formulated as a softgel capsule containing a synergistic combination of active ingredients, including methylcobalamin, coenzyme Q10, levocarnitine, alpha-linolenic acid, linolenic acid, levomefolic acid, lycopene, oleic acid, piperine, pyridoxal 5-phosphate, and tocotrienol. These components work together to support nerve health, reduce oxidative stress, promote nerve repair, and address nutritional gaps associated with neuropathic conditions.

Brand names: Mecoturn Q10
Other names: Mecoturn Q10 Softgel Capsule

Targets

MTR (Methionine synthase)

Beyond the preview

Go deeper on Mecoturn Q10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mecoturn Q10.

Explore the full profile